Alcohol Use Disorder

Alcohol use disorder remains the most prevalent substance use disorder yet the most undertreated, with fewer than ten percent of patients receiving evidence-based pharmacotherapy. The track will cover the established triad — naltrexone (oral and extended-release), acamprosate, and disulfiram — alongside off-label evidence for topiramate, gabapentin, and baclofen. A dedicated session will examine the rapidly accumulating signal that GLP-1 receptor agonists (semaglutide, tirzepatide) reduce alcohol craving and consumption, including readouts from semaglutide AUD trials. Behavioral content covers CBT, MET, the COMBINE study legacy, and integration of AUDIT-C screening into primary care.